| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/07/2022 | 15.03% | Morgan Stanley | → $7.5 | Initiates Coverage On | → Equal-Weight |
| 09/29/2022 | 7.36% | B of A Securities | → $7 | Initiates Coverage On | → Buy |
| 09/23/2022 | 84.05% | Chardan Capital | → $12 | Initiates Coverage On | → Buy |
Senti Biosciences Questions & Answers
The latest price target for Senti Biosciences (NASDAQ: SNTI) was reported by Morgan Stanley on October 7, 2022. The analyst firm set a price target for $7.50 expecting SNTI to rise to within 12 months (a possible 15.03% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Senti Biosciences (NASDAQ: SNTI) was provided by Morgan Stanley, and Senti Biosciences initiated their equal-weight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Senti Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Senti Biosciences was filed on October 7, 2022 so you should expect the next rating to be made available sometime around October 7, 2023.
While ratings are subjective and will change, the latest Senti Biosciences (SNTI) rating was a initiated with a price target of $0.00 to $7.50. The current price Senti Biosciences (SNTI) is trading at is $6.52, which is within the analyst's predicted range.